Roche’s Alzheimer’s Drug Fails In Phase III Giving Eisai/Biogen A Clear Run

Fails To Produce Significant Slowing Of Disease

Roche’s gantenerumab has failed to make the grade in its GRADUATE studies, leaving the field wide open for Eisai and Biogen’s lecanemab.

Eisai and Biogen look set to have a clear run at the Alzheimer’s disease market now that Roche’s rival candidate, gantenerumab, is out of the running after it failed in its two Phase III GRADUATE studies.

Gantenerumab did not significantly slow the progression of Alzheimer’s in the twin studies involving

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Lundbeck Lifted By Leap In Migraine Therapy Sales

14 May 2025

• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

13 May 2025

• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.